Bupivacaine buccal - Moberg Pharma

Drug Profile

Bupivacaine buccal - Moberg Pharma

Alternative Names: BUPI; BUPI-25; Bupizenge

Latest Information Update: 04 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oracain
  • Developer Hvidovre Hospital; Moberg Pharma
  • Class Anilides; Local anaesthetics; Non-opioid analgesics; Pipecolic acids; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Dental pain; Inflammatory pain

Most Recent Events

  • 01 Sep 2017 Moberg Pharma has patent protection for bupivacaine buccal in Canada
  • 19 Oct 2016 Moberg Pharma has patent protection for bupivacaine buccal in European Union
  • 16 Aug 2016 Hvidovre University Hospital and Moberg Pharma discontinue a phase II trial for Inflammatory pain in Denmark (EudarCT2013-000343-11)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top